Duchenne muscular dystrophy (DMD) is a progressive, inherited muscle-wasting disease that mainly affects boys. A decade of new approvals has widened treatment options, but the first gene therapy, Elevidys, has become the field's most contested product after a missed trial endpoint, fatal liver injuries and a narrowed label.
Core Patient Information
What is Duchenne muscular dystrophy?
Duchenne muscular dystrophy (DMD) is an inherited disease in which muscle fibers progressively break down because the body cannot make working dystrophin, a protein that helps keep muscle cell membranes intact. It is the most common muscular dystrophy of childhood, with incidence usually estimated at about 1 in 3,500 male births. Weakness typically begins in the hips, thighs and shoulders and later spreads to the arms, the heart and the muscles used for breathing.
Boys are usually diagnosed at close to age five, and many need a wheelchair between roughly ages 7 and 13. Heart and respiratory complications are the main causes of death. Becker muscular dystrophy is a milder condition caused by partly working dystrophin. DMD is rare but well defined: a known gene, a predictable course and a growing list of approved therapies make it one of the most heavily invested rare-disease markets.
What are the early signs of Duchenne muscular dystrophy?
Parents often first notice that a toddler walks late, falls frequently, runs awkwardly or struggles with stairs. A classic sign is difficulty rising from the floor, where a child pushes up by walking his hands up his thighs, known as the Gowers maneuver. Other early signs include walking on tiptoes, a waddling gait, unusually large calf muscles and, in some boys, delayed speech or learning difficulties.
Because these signs overlap with normal developmental variation, diagnosis is often delayed, and diagnosis typically comes around age 4 to 5, years after the first clues. A blood test for creatine kinase, a muscle enzyme that leaks into the bloodstream when muscle is damaged, is the usual first step. Anyone worried about a child's motor development should ask a pediatrician about creatine kinase testing rather than waiting, because several treatments are restricted by age and walking ability.
What causes Duchenne muscular dystrophy?
DMD is caused by changes in the DMD gene on the X chromosome, one of the largest genes in the human genome, which holds the instructions for dystrophin. Without dystrophin, muscle cell membranes tear during normal contraction, muscle fibers die and fat and scar tissue replace them. Whole-exon deletions and duplications are common, although smaller sequence changes also occur. The exact change matters for treatment, because exon-skipping drugs only work for specific deletions: Exondys 51, Vyondys 53 and Amondys 45 each target a different exon.
Roughly one-third of cases arise from new mutations in families with no earlier history, while the rest are inherited through carrier mothers. Nothing a parent does before or during pregnancy causes DMD. Confirming the precise variant through genetic testing is now routine because it determines eligibility for several therapies.
Is Duchenne muscular dystrophy inherited from the mother?
Often, but not always. DMD follows an X-linked recessive pattern, so most affected boys inherit the altered gene from a mother who carries it. Carrier mothers frequently have no symptoms and may not know they carry the variant until a son is diagnosed. Each son of a carrier has a 50% chance of being affected, and each daughter has a 50% chance of being a carrier. A father cannot pass the condition to his sons, because they inherit his Y chromosome.
About one-third of boys have a new mutation, meaning their mother is not a carrier, although a small recurrence risk remains because of germline mosaicism, where some of a parent's egg cells carry the change. Genetic counseling and carrier testing are recommended for mothers and female relatives after a diagnosis, particularly before another pregnancy.
Why does Duchenne muscular dystrophy mainly affect boys?
Boys are affected because the DMD gene sits on the X chromosome and males have only one. A boy who inherits an altered copy has no second copy to compensate, so dystrophin is missing and symptoms follow. Girls have two X chromosomes, and a working copy usually produces enough dystrophin to protect muscle, so females are typically carriers rather than patients.
However, in each cell one X chromosome is randomly switched off, a process called X-inactivation. If the working copy happens to be switched off in many muscle cells, a female carrier can develop symptoms, ranging from mild weakness to, rarely, heart involvement or more significant disease. These women are called manifesting carriers. Girls with full-blown DMD are very uncommon and generally have unusual genetic circumstances. Clinical trials have enrolled mostly boys, so treatment data in females remain limited.
How is Duchenne muscular dystrophy diagnosed?
Diagnosis usually begins with a clinical exam and a blood test for creatine kinase (CK). In DMD, CK is markedly elevated, although the finding is not specific to this disease. The confirmatory step is genetic testing of the DMD gene for deletions, duplications and smaller variants, which confirms the clinical diagnosis in affected males.
If genetic testing is negative or unclear, a muscle biopsy can show whether dystrophin is absent. Knowing the exact variant matters for therapy, because exon-skipping drugs depend on it and Elevidys is not used in patients with deletions in exons 8 or 9. The main unmet need is timing: with most boys diagnosed near age five, irreversible muscle loss has already begun, and some treatments have narrow age windows, which is why earlier diagnosis is a stated priority for advocates and companies alike.
What is the life expectancy for someone with Duchenne muscular dystrophy?
Without modern care, the mean age at death was historically around 19 years. Survival has improved with corticosteroids, spinal and orthopedic care, nighttime ventilation and heart medicines. Roche has cited an average life expectancy of 28 years, while a health-plan policy summary says respiratory, cardiac, orthopedic and rehabilitative care plus steroids can extend life expectancy up to 40 years.
Pediatric neurologist Nancy Kuntz told a 2024 AANEM session that when she trained, boys were expected to stop walking by age 10 and die around 20. Outcomes vary with access to multidisciplinary clinics, steroid use and the type of DMD variant. Heart and respiratory failure remain the leading causes of death, and the long-term survival effect of newer drugs is still being studied. Careful comparisons across studies are difficult because older estimates reflect earlier eras of care.
Is there a cure for Duchenne muscular dystrophy?
There is no cure for DMD. Treatments aim to slow decline and manage complications. Elevidys, approved in 2023, is the first gene therapy for DMD, delivering a shortened version of the dystrophin gene (micro-dystrophin) using an adeno-associated virus vector. It is not a cure. Its phase 3 EMBARK trial missed the primary endpoint, European regulators declined to recommend it, and in the U.S. its label is now limited to patients who can still walk and carries a boxed warning for liver injury.
Roche describes the therapy as providing stabilization or slowing of disease progression rather than restoring lost function. Exon-skipping drugs, steroids and newer agents also modify rather than eliminate the disease. Families should treat any claim of a cure with caution and discuss realistic goals with a neuromuscular specialist.
What treatments are available for Duchenne muscular dystrophy?
Corticosteroids remain the backbone: prednisone and deflazacort (Emflaza and generics) are the long-standing options, and vamorolone (Agamree) is a newer "dissociative" steroid designed to be better tolerated. Givinostat (Duvyzat), a histone deacetylase inhibitor, is approved for boys six and older regardless of variant. Four exon-skipping drugs, Exondys 51, Vyondys 53, Amondys 45 and Viltepso, treat boys with matching deletions, and Sarepta has applied to convert two of them from accelerated to traditional approval.
Elevidys gene therapy is available to ambulatory patients age four and older. Long-term steroid side effects, including growth delay and bone thinning, are one reason newer options are being adopted earlier, yet specialist Nancy Kuntz said steroids can "add months and years" to life. Cardiology, pulmonary care, physical therapy, bone-health management and scoliosis surgery are equally important. One AANEM presenter noted that eight DMD-specific therapies have been approved in eight years.
Market and Controversy Information
Why is Elevidys controversial?
Elevidys (delandistrogene moxeparvovec), made by Sarepta Therapeutics, has drawn criticism on four fronts. First, the FDA granted accelerated approval on June 22, 2023 based on micro-dystrophin expression, not proven clinical benefit. Second, the confirmatory EMBARK trial missed its primary endpoint, yet the label was expanded in June 2024. Third, deaths from acute liver failure in non-ambulatory patients led to an FDA safety communication in June 2025 and a boxed warning in November 2025.
Fourth, the therapy lists at $3.2 million. Sarepta agreed to the label changes and said it would study a stronger immunosuppression regimen, and Sarepta and Roche maintain that the benefit-risk profile remains positive in ambulatory patients, while critics, including Doctors for America, argue the evidence was insufficient. The following answers cover each issue in turn, with the parties and dates involved.
How effective is Elevidys for Duchenne muscular dystrophy?
The evidence is mixed. In the phase 3 EMBARK study of 125 boys aged four to seven, treated patients improved 2.6 points on the North Star Ambulatory Assessment versus 1.9 points for placebo, a difference that was not statistically significant. Sarepta pointed to secondary measures, including time to rise and the 10-meter walk, that favored treatment, but the FDA typically does not consider secondary results positive when the primary endpoint fails.
The earlier Study 102 also missed its primary endpoint. The European regulator's committee noted that dystrophin levels could not be linked to improved movement. Roche says two-year EMBARK data and pooled three-year analyses show clinically meaningful stabilization. Younger boys appeared to do better than older ones, which is consistent with a disease where lost muscle cannot easily be restored.
Why did the FDA approve Elevidys despite uncertainty over its clinical benefit?
The 2023 approval used the accelerated pathway, which allows a surrogate marker reasonably likely to predict benefit. For Elevidys the surrogate was micro-dystrophin expression in muscle. Then-CBER director Peter Marks said the approval addressed an urgent unmet need. After EMBARK missed its primary endpoint, the FDA in June 2024 granted full approval based on secondary endpoint improvements in ambulatory patients and accelerated approval in non-ambulatory patients.
Critics say the decision was contested internally: Doctors for America stated that three review teams objected, and Vinay Prasad, later Marks's successor, publicly accused Marks of overruling reviewers. Marks stepped down in March 2025. The FDA has not withdrawn the approval; in November 2025 it instead narrowed the label to ambulatory patients and added the boxed warning. When Prasad was named to lead the biologics center, investors reacted negatively because of his long-standing public criticism of Sarepta's therapies.
Is Elevidys safe following reports of serious liver injury and patient deaths?
Elevidys carries a boxed warning for acute serious liver injury and acute liver failure. In June 2025 the FDA reported two fatal acute liver failure cases in non-ambulatory boys, plus a non-fatal case complicated by bowel ischemia and portal hypertension. Sarepta's label update, announced November 2025, removed the non-ambulatory indication, advised against use in people with preexisting liver impairment and requires patients to stay near a health facility for at least two months.
The Parent Project Muscular Dystrophy summary notes weekly liver tests for at least three months. The FDA also required a postmarketing observational study of 200 patients. Sarepta has said it plans to test an enhanced immunosuppression regimen with sirolimus in non-ambulatory patients. Ambulatory patients remain eligible, but families and physicians must weigh a real risk of fatal liver injury against uncertain functional benefit.
Why does Elevidys cost more than $3 million?
Sarepta set a wholesale acquisition cost of $3.2 million at launch in June 2023 for a one-time infusion. Chief executive Doug Ingram called it a conservative reflection of value and cited a company-sponsored analysis suggesting the therapy could be cost-effective at $5 million to $13 million versus standard care. Sarepta expected statutory discounts to leave net revenue about 20% lower, and one analyst estimated gross-to-net in the mid-20% range.
Sarepta did not expect many insurer barriers because the eligible population is small. A pharmacist at Optum Rx noted the price is in line with other gene therapies priced $2.1 million to $3.5 million. Critics disagree: ICER's chief medical officer David Rind raised the price and the missed endpoints in a JAMA commentary, and Prasad has called the product one of the most costly drugs in history, a view he published in a 2024 letter with a co-author.
How have safety concerns affected access to Elevidys in the US and Europe?
In the U.S., access narrowed. After the deaths, Elevidys is indicated only for ambulatory patients aged four and older. Sarepta had earlier set a yearly sales floor of $500 million for the product and attributes falling revenue to the label change: second-quarter 2026 Elevidys net revenue was $98.1 million, compared with $898.7 million for full-year 2025. Eligibility is further limited because baseline testing for pre-existing antibodies to the viral vector is required. In Europe, the EMA's committee issued a negative opinion on July 25, 2025, and Roche said it would continue dialogue with the agency.
How big is the Duchenne market, who are the key players and what is the outlook?
Sarepta dominates. Its DMD products generated $1.86 billion in net product revenue in 2025, split between Elevidys ($898.7 million) and its exon-skipping drugs ($965.6 million). For 2026 it guided to $1.2 billion to $1.3 billion, a decline, and appointed Michael Severino as chief executive effective July 28, 2026. Elevidys sold $102.0 million in the first quarter and $98.1 million in the second quarter of 2026.
Roche holds ex-U.S. rights to the therapy, and Sarepta is shifting research toward siRNA programs. Other players include Catalyst and Santhera, which market Agamree. Outlook hinges on three things: whether Sarepta can convert its exon-skipping approvals to traditional status, whether Elevidys can recover with a safer regimen, and whether next-generation gene and exon-skipping candidates reach the market. The updated prescribing information was revised in August 2026.